Enrolment in this trial is expected to continue through the first quarter of 2025. Satellos is on track to submit a Phase II ...

The University of Rochester will confront significant blows to groundbreaking clinical studies, UR says in a legal challenge to cuts in NIH funding.

Regenxbio's gene therapy faces market challenges as Goldman Sachs lowers its rating and price target, citing competition and ...